Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

The Multibillion-Dollar Battle For Metsera’s Obesity Drugs

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, ...
Fierce Biotech

Pfizer beats out Novo with $10B agreement to buy Metsera

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has ...
BioSpace

Is Metsera Worth The Fuss?

Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

(NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per ...